CN101346381A - New anti-malaria derivatives of 4-aminoquinoline - Google Patents

New anti-malaria derivatives of 4-aminoquinoline Download PDF

Info

Publication number
CN101346381A
CN101346381A CNA2006800486047A CN200680048604A CN101346381A CN 101346381 A CN101346381 A CN 101346381A CN A2006800486047 A CNA2006800486047 A CN A2006800486047A CN 200680048604 A CN200680048604 A CN 200680048604A CN 101346381 A CN101346381 A CN 101346381A
Authority
CN
China
Prior art keywords
compound
methyl
pyrroles
chloro
amine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800486047A
Other languages
Chinese (zh)
Inventor
F·斯派拉托尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Need Pharmaceuticals S R L
NEED PHARMACEUTICALS Srl
Original Assignee
Need Pharmaceuticals S R L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Need Pharmaceuticals S R L filed Critical Need Pharmaceuticals S R L
Publication of CN101346381A publication Critical patent/CN101346381A/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D455/00—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02—Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

New derivatives of 4-aminoquinoline which have a general formula A-X-Y-T where A is a 4-aminoquinolinic nucleus, X and Y are spacers and T represents a nitrogenous ring or an aminic group, substituted if necessary. These are powerful antimalarial compounds active on both chloroquine-sensitive and chloroquine-resistant strains of Plasmodium falciparum.

Description

Novel anti-malaria derivatives of 4-aminoquinoline
Technical field
The present invention relates to novel antimalarial compound, particularly have the derivative of the 4-quinolylamine of western pyridine ring in quinolixiding and the pyrroles.
Background of invention
In developing country, malaria remains the most serious wherein a kind of disease, and 1 to 3 million people's death is arranged every year, 3 to 500,000,000 cases.The most serious malaria form is caused by plasmodium falciparum.
Antimalarial two kinds of the most frequently used medicines are chloroquine and sulfadoxine-pyrimethamine, but have become the area of endemic in most of malaria, and their effect becomes worse and worse, and the result is that the M ﹠ M relevant with malaria is more and more higher.The major cause of this shortage effect has generally had tangible resistance and structure unrelated drugs to exist crossed resistance relevant with parasite to common anti-malaria medicaments.
Resist malaria, very need new medicine, particularly for the effective new drug of drug resistant falciparum malaria protozoon bacterial strain.Ideal situation is, it is effective that new malaria medicine should resist medicated strain, reasonably playing a role in the time (ideal is 3 days or following), obtain good therapeutic action, child, pregnant woman are good to its resistance, but also cheap (D.A.Fidock etc., Antimalarial drug discovery:efficacy models forcompound screening, Nature Reviews 3,509-520 (2004)).
Summary of the invention
The 4-aminoquinoline derivatives anti-malarial of novelty of the present invention is effectively, and also is activated for the plasmodium falciparum strain of anti-chloroquine.
Compound of the present invention such as following general formula are represented:
Figure A20068004860400041
In the formula,
R is Cl, Br, trifluoromethyl;
M be 0 or part in Au, Rh, Ru; Described part is selected from PR ' 3, wherein: when M was gold, R ' was phenyl or C2-C4 alkyl; When M is rhodium, R ’ Shi Ring octadiene; When M was ruthenium, R ' was second same quinoline acidic group; When M is gold, can there be PF 6 -Or NO 3 -Group; When M is rhodium or ruthenium, can there be Cl -
X is the group shown in the following formula,
Figure A20068004860400051
Wherein R2 and R3 can be identical or different, can be H or straight or branched alkyl, are preferably (CH 2) n-CH 3, wherein n=0-10 better is 1-3, or with-CH 3,-OCH 3,-CF 3, F, Cl, Br are single replaces or disubstituted phenyl ring;
Y is CH 2-(NH) n-(CH 2) m, n=0,1 wherein, m=0-10 is preferably 1-3;
T is the group shown in the following formula:
T also can be the group shown in the following formula,
Figure A20068004860400053
T can also be the group shown in the following formula,
Figure A20068004860400054
Wherein, R4 and R5 can be identical or different, can be H or straight or branched alkyl, are preferably (CH 2) n-CH 3, n=0-5 wherein, perhaps R4 and R5 form ring together, for example 5 of pyrrolidines yuan of rings.
Preferred compounds of the invention are following compounds:
Figure A20068004860400061
(7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(four Hydrogen-pyrrolizine-7a-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine;
Figure A20068004860400062
(7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(eight Hydrogen-quinolizine-1-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine;
(7-chloro-quinolyl-4)-[2,5-dimethyl-3-(tetramethyleneimine-1-ylmethyl)-pyrroles-1-yl]-amine;
Figure A20068004860400071
(7-chloro-quinolyl-4)-(3-diethylamino methyl-2,5-dimethyl-pyrroles-1-yl)-amine;
Figure A20068004860400072
[3-(tributyl amino-methyl)-2,5-dimethyl-pyrroles-1-yl]-(7-chloro-quinolyl-4)-amine;
Figure A20068004860400073
(7-chloro-quinolyl-4)-(3-diethylamino methyl-2-methyl-5-phenyl-pyrroles-1-yl)-amine;
Figure A20068004860400081
(7-chloro-quinolyl-4)-(3-diethylamino methyl-2-phenyl-5-methyl-pyrroles-1-yl)-amine.
According to the present invention, above-mentioned two kinds of compounds (7-chloro-quinolyl-4)-(3-diethylamino methyl-2-methyl-5-phenyl-pyrroles-1-yl)-amine and (7-chloro-quinolyl-4)-(3-diethylamino methyl-2-phenyl-5-methyl-pyrroles-1-yl)-amine can obtain with form of mixtures, and their ratios in mixture can be different from confirmable.Advantageously, above-claimed cpd can be to use individually, also can form the mixture of variable ratio and uses.
Figure A20068004860400082
7-chloro-N-(2-methyl-5-phenyl-3-(tetramethyleneimine-1-ylmethyl)-1H-pyrroles-1-yl) quinoline-4-amine
Vitro test the effect of compound of the present invention for the plasmodium falciparum strain of and anti-chloroquine responsive to chloroquine, their IC 50Value is between 10 to 200ng/ml.
The abdominal cavity give with oral compound of the present invention after, the body build-in test their effect, find they effect and chloroquine quite or better.In addition, the toxicity of these compounds in mammalian cell (WEHI clones 13 mouse cells) is very low, its IC 50＞10000nM.
Pharmacy acceptable salt, for example mineral acid and organic acid, amino acid whose salt also constitute a part of the present invention.Preferable salt is hydrochloride, phosphoric acid salt, vitriol, Citrate trianion and fumarate.
The particular case of Zhi Liao disease or state as required, the amount that patient accepts compound of the present invention is that treatment is gone up effectively and well-tolerated, this can be determined by those skilled in the art.For example, compound per daily dose of the present invention is approximately 1 to 60mg/kg, is preferably 3 to 30mg/kg.
Compound of the present invention also can use with the form of capacity formulation, and the character of use depends on selected medication.
According to conventional methods, adopt compatible pharmaceutically acceptable vehicle or carrier to can be made into pharmaceutical compositions.
For example, pharmaceutical compositions comprises capsule, tablet, syrup, pulvis and granula, make instant solution, injectable, rectum gives and nose in the preparation that gives.Preferred medication is oral.
Following examples are unrestricted, only further describe the present invention, for those skilled in the art preparation with use compound of the present invention.
Embodiment
Synthesizing of embodiment 1. (7-chloro-quinolyl-4)-(2,5-dimethyl-pyrroles-1-yl)-amine
767mg (6.72mmoles) acetonyl-acetone is added in the suspension of being made up of 5.6ml Glacial acetic acid and 1.084g (5.6mmoles) 7-chloro-4-diazanyl quinolylamine (Aldrich).This suspension is heated to 65 ℃, kept 3 hours.Evaporate acetic acid, roughage reclaims with the water of ammoniacal liquor alkalization.Filter to isolate throw out, wash with water, silica gel flash chromatography method purifying, the eluent mixture that this chromatography adopts is the methylene dichloride that contains 1% methyl alcohol.Use the diethyl ether washed product, its fusing point is 225.8-227.5 ℃.
Embodiment 2. (7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(eight Hydrogen-quinolizine-1-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine synthetic
Putting into the amino lupinane dihydrochloride of 530mg (2.2mmoles) in the 10ml round-bottomed flask (makes in the method that Farmaco Ed.Sci. describes according to people such as F.Sparatore, 1969,24, p.587-621), 0.19ml (2.2mmoles) 37% formaldehyde and 0.67ml Glacial acetic acid.Mixture reacts under agitation condition, transfers to then in the 50ml two neck round-bottomed flasks that contain 544mg (2mmoles) (7-chloro-quinolyl-4)-(2,5-dimethyl pyrrole-1-yl)-amine (method of pressing embodiment 1 is made).Under nitrogen atmosphere, reaction mixture stirred 2 hours.The roughage water that obtains reclaims, and the chloroform extraction suspension is used in the alkalization of 20% sodium hydroxide in separatory funnel.After the sodium sulfate dehydration, organic phase is evaporated to drying.Silica gel purification solid, elutriant are CH 2Cl 2, CH 3OH and NH 3(96: 3.6: 0.4) mixture.Component after the evaporation is washed with diethyl ether, obtains product, 188-191 ℃ of its fusing point.
Synthesizing of embodiment 3. (7-chloro-quinolyl-4)-(3-diethylamino methyl-2,5-dimethyl-pyrroles-1-yl)-amine
In the 5ml flask, put into 0.16ml (1.5mmoles) diethylamine, 0.13ml (1.5mmoles) 37% formaldehyde and 0.5ml Glacial acetic acid.The solution that obtains reacts under 0 ℃ and agitation condition, is transferred to then in the 50ml flask that contains 408mg (1.5mmoles) (7-chloro-quinolyl-4)-(2,5-dimethyl-pyrroles-1-yl)-amine (press the method making of embodiment 1).Nitrogen atmosphere and 25 ℃ of following stirrings 2 hours.Mixture is suspended from water and the 2N sodium hydroxide, arrives the alkaline pH value until it, uses dichloromethane extraction then.After the evaporation organic phase, residue silicon-dioxide column purification, elutriant are CH 2Cl 2, CH 3OH and NH 3(97: 2,7: 0,3) mixture.Component after the evaporation obtains product with the mixture washing in 70: 30 of diethyl ether/sherwood oil, and its fusing point is 248-251 ℃, can decompose.
Embodiment 4.[3-(tributyl amino-methyl)-2,5-dimethyl-pyrroles-1-yl]-(7-chloro-quinolyl-4)-amine synthetic
In the 5ml round-bottomed flask, put into 0.17ml (1.65mmoles) TERTIARY BUTYL AMINE, 0.14ml (1.65mmoles) 37% formaldehyde and 0.5ml Glacial acetic acid.The solution that obtains is reacted, be transferred to then in the 50ml round-bottomed flask that contains 408mg (1.5mmoles) (7-chloro-quinolyl-4)-(2,5-dimethyl-pyrroles-1-yl)-amine.Reaction is 2 hours under nitrogen atmosphere and agitation condition.The roughage water that obtains reclaims, the alkalization of 20% sodium hydroxide.The suspension that obtains is transferred to separatory funnel, uses dichloromethane extraction.After the sodium sulfate dehydration, organic phase is evaporated to drying, the solid that obtains silica gel flash chromatography method purifying, elutriant is CH 2Cl 2, CH 3OH and NH 3(96: 3.6: 0.4) mixture.The product that obtains reclaims with hexanaphthene/diethyl ether at 50: 50, filters, and evaporating solns obtains product, 101.2-103.5 ℃ of its fusing point.
Embodiment 5. (7-chloro-quinolyl-4)-[2,5-dimethyl-3-(tetramethyleneimine-1-ylmethyl)-pyrroles-1-yl]-amine
In the 5ml flask, put into 0.13ml (1.5mmoles) tetramethyleneimine, 0.13ml (1.5mmoles) 37% formaldehyde and 0.5ml Glacial acetic acid.The solution that obtains reacts under 0 ℃ and agitation condition, is transferred to then in the 50ml flask that contains 408mg (1.5mmoles) (7-chloro-quinolyl-4)-(2,5-dimethyl-Bi Ka And-1-yls)-amine (press the method making of embodiment 1).Reaction is 2 hours under nitrogen atmosphere and agitation condition.Add 20% sodium hydroxide to mixture, until arriving alkaline pH value, product dichloromethane extraction then.After the evaporation organic phase, thick residue column purification, elutriant is the mixture of methylene dichloride in methyl alcohol, the highest gradient is that concentration is 20%.The fusing point of product is 164-166 ℃.
The preparation of embodiment 6.7-chloro-N-(3-((diethylamino) methyl)-2-methyl-5-phenyl-1H-pyrroles-1-yl) quinoline-4-amine
6.1.2-ethanoyl-4-oxo-4-phenylbutyrate
Figure A20068004860400111
Put into 20ml anhydrous diethyl ether and 230mg (10mmoles) fine metal sodium in three neck round-bottomed flasks, described flask is furnished with the reflux exchanger by the calcium chloride valve protection.
Splash into 1.52ml (12mmoles) methyl aceto acetate in the 2ml anhydrous diethyl ether to described solution.
Mixture is reflux under nitrogen gas stream and agitation condition, until the sodium Metal 99.5 completely dissolve.Simultaneously, form the sodium salt of white solid methyl aceto acetate.
In the suspension that obtains, splash into by 2g (10mmoles) bromoacetophenone and be dissolved in solution in the 26ml anhydrous diethyl ether, be cooled to room temperature then.After above-mentioned solution added, about 2 hours of mixture reflux leached Sodium Bromide then, and organic phase is through reduction vaporization.
By the silica gel tlc monitoring reaction course, elutriant adopts CH 2Cl 2/ ethyl acetate (10: 1).
Roughage is with silica gel flash chromatography method purifying, and elutriant is a gradient from 60: 40 to 30: 70 hexanaphthene and dichloromethane mixture.Obtain the 2.2g water white oil, its yield is 88%.
(6.2.1-7-chloroquinoline-4-base is amino)-2-methyl-5-phenyl-1H-pyrroles-3-carboxylic acid, ethyl ester
Figure A20068004860400112
1.2g (6.2mmoles) 2-ethanoyl-4-oxo-4-phenylbutyrate is dropwise splashed in the solution of being made up of 7ml Glacial acetic acid and 1.2g (6.2mmoles) 7-chloro-4-diazanyl quinoline, and described solution is contained in 25ml to be furnished with in the backflow two neck flasks of calcium chloride valve.
In case after above-mentioned adding was finished, the backflow heated solution was 2 hours under nitrogen atmosphere and agitation condition.
By the silica gel tlc monitoring reaction course, elutriant adopts ethyl acetate/hexanaphthene (7: 3).
In reaction process, it is xanchromatic that solution begins, and transfers brown afterwards to.
After 2 hours, solution reclaims with methylene dichloride, and the organic phase that obtains is washed up hill and dale with freezing 1N sodium hydroxide solution, becomes alkalescence until the water that washs usefulness.
Water is reconsolidated, and alkalization once more is with a large amount of dichloromethane extractions.
Reconsolidate organic phase, anhydrous sodium sulfate dehydration steams to dry.
The roughage that obtains silica gel flash chromatography method purifying, elutriant is cyclohexane/ethyl acetate mixture (60: 40).
Behind the recrystallization, obtain the 1.98g solid in diethyl ether/sherwood oil, be white paste, fusing point is 165-168 ℃.The reaction yield is 79%.
(6.3.1-7-chloroquinoline-4-base is amino)-N, N-diethyl-2-methyl-5-phenyl-1H-pyrroles-3-carboxylic acid amides
Figure A20068004860400121
The three neck round-bottomed flasks that to be furnished with by calcium chloride valve protection reflux exchanger are placed in the ice bath.In flask, put into 6ml dry toluene and 0.081ml (0.78mmoles) diethylamine.Under induction stirring, splash into the trimethyl aluminium of 0.4ml 2M (0.8mmoles) in toluene to frozen soln.
In case above-mentioned adding is finished, allow about 1 hour of solution room temperature reaction under nitrogen atmosphere and agitation condition.
Then, add 250mg (0.62mmoles) 1-(7-chloroquinoline-4-base is amino)-2-methyl-5-phenyl-1H-pyrroles-3-carboxylic acid, ethyl ester, about 24 hours of the suspension that obtains reflux under nitrogen atmosphere and agitation condition forms yellow solution therebetween, transfers brown again to.
By the silica gel tlc monitoring reaction course, elutriant adopts methylene chloride (10: 0.5).
After having spent 24 hours, reclaim solution with a large amount of ethyl acetate, add the freezing sodium hydroxide solution of 1N to organic phase, formation aluminium hydroxide also leaches.
After aqueous phase separation, the organic phase dehydration, and dry.
Roughage silica gel flash chromatography method purifying, elutriant is the mixture that contains the methylene dichloride of 0.5-2% methyl alcohol.
After the washing of ethanol/diethyl ether (7: 3) mixture, obtain 135mg crystalline solid, yield is 51%.
6.4.7-chloro-N-(3-((diethylamino) methyl)-2-methyl-5-phenyl-1H-pyrroles-1-yl) quinoline-4-amine (CM7/I)
Figure A20068004860400131
With 120mg (0.28mmoles) 1-(7-chloroquinoline-4-base amino)-N, N-diethyl-2-methyl-5-phenyl-1H-pyrroles-3-carboxylic acid amides is divided into small portion and joins 120mg (3.16mmoles) LiAlH in the 10ml anhydrous diethyl ether 4Suspension in, this suspension is placed in the two neck round-bottomed flasks of being furnished with reflux exchanger.After in case above-mentioned adding is finished, about 4 hours of suspension reflux under nitrogen and agitation condition.
By the silica gel tlc monitoring reaction course, elutriant adopts CH 2Cl 2/ methyl alcohol/NH 3(10/1/0.1).
After having spent 4 hours, the reaction suspension is handled with the 1N sodium hydroxide solution, and formation aluminium hydroxide also leaches.
After aqueous phase separation, the organic phase dehydration, and dry.Roughage silica gel flash chromatography method purifying, elutriant is the mixture that contains the methylene dichloride of 1-7% methyl alcohol.
Behind methylene dichloride/petroleum ether mixture, obtain the 76mg solid, but fusing point and decomposition point are between 156.5 to 160 ℃.
The reaction yield is 65.5%.
Similarly, adopt suitable reagent and parent material, synthetic (7-chloro-quinolyl-4)-(3-diethylamino methyl-2-phenyl-5-methyl-pyrroles-1-yl)-amine (CM7/II).
The preparation of embodiment 7.7-chloro-N-(2-methyl-5-phenyl-3-(tetramethyleneimine-1-ylmethyl)-1H-pyrroles-1-yl) quinoline-4-amine
(7.1. 1-(7-chloroquinoline-4-base is amino)-2-methyl-5-phenyl-1H-pyrroles-3-yl) (tetramethyleneimine-1-yl) Mei Shedong (methadone)
Figure A20068004860400141
The three neck round-bottomed flasks that to be furnished with by calcium chloride valve protection reflux exchanger are placed in the ice bath.In flask, put into 6ml dry toluene and 0.07ml (0.78mmoles) tetramethyleneimine.Under induction stirring, splash into the trimethyl aluminium of 0.4ml2M (0.8mmoles) in toluene to frozen soln.
In case above-mentioned adding is finished, allow about 1 hour of solution room temperature reaction under nitrogen atmosphere and agitation condition.
Then, add 250mg (0.62mmoles) 1-(7-chloroquinoline-4-base is amino)-2-methyl-5-phenyl-1H-pyrroles-3-carboxylic acid, ethyl ester, the suspension that obtains about 24 hours of reflux under nitrogen atmosphere and induction stirring condition forms yellow solution therebetween, transfers the brown precipitation again to.
By the silica gel tlc monitoring reaction course, elutriant adopts methylene chloride (10: 1).
After having spent 24 hours, leach solid also with a large amount of toluene and diethyl ether washing; The control of TLC confirms to obtain needed product.
Obtain the 220mg acid amides at last, yield is 86%.
7.2.7-chloro-N-(2-methyl-5-phenyl-3-(tetramethyleneimine-1-ylmethyl)-1H-pyrroles-1-yl) quinoline-4-amine
Figure A20068004860400142
200mg (0.28mmoles) (1-(7-chloroquinoline-4-base amino)-2-methyl-5-phenyl-1H-pyrroles-3-yl) (tetramethyleneimine-1-yl) Mei Shedong is divided into small portion joins 230mg (6.06mmoles) LiAlH in the 20ml anhydrous diethyl ether 4Suspension in, this suspension is placed in the two neck round-bottomed flasks of being furnished with reflux exchanger.
After in case above-mentioned adding is finished, about 4 hours of suspension reflux under nitrogen and agitation condition.
By the silica gel tlc monitoring reaction course, elutriant adopts CH 2Cl 2/ methyl alcohol/NH 3(10/1/0.1).
After having spent 4 hours, the reaction suspension is handled with the 1N sodium hydroxide solution, and formation aluminium hydroxide also leaches.
After aqueous phase separation, the organic phase dehydration, and dry.Roughage silica gel flash chromatography method purifying, elutriant is the mixture that contains the methylene dichloride of 1-6% methyl alcohol.
After the diethyl ether washing, obtain the 95mg solid, fusing point is between 172.5 to 176 ℃.
The reaction yield is 51%.
The Au composite of embodiment 8. embodiment 2 compounds
Reflux down, 200mg (0.4mmoles) triphenylphosphine gold trichloride is dissolved in the 20ml acetonitrile, the solution that obtains joins 148.8mg (0.8mmoles) Potassium Hexafluorophosphate (KPF 6) in, heated 30 minutes.Add 371mg (0.82mmoles) (7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(eight Hydrogen-quinolizine-1-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine, mixture keeps refluxing 48 hours, after the cooling, leaches the throw out that obtains.
Concentrated filtrate adds several ethers, is placed in the refrigerator.The solid of separating is filtered off, with the washing of anhydrous ether/acetonitrile (1/3) mixture.Concentrated solution is handled with ether once more, is placed in the refrigerator.Repeat this program repeatedly, all filter out throw out at every turn.At last, solution steams to dry, with ether wash residual thing, and dry.
Embodiment 9. biological datas
Vitro test compound of the present invention finds that they all are effective for plasmodium falciparum strain (CQ-S) D10 of chloroquine sensitivity and plasmodium falciparum strain (CQ-R) W2 of anti-chloroquine.Test result is listed in the table below.
Compound D10(CQ-S) (IC 50ng/ml) W2(CQ-R) (IC 50ng/ml)
Embodiment 2 32.0±2.4 24.2±7.4
Embodiment 3 24.6±9.0 68.8±1.4
Embodiment 4 17.4±3.7 91.1±19.2
Embodiment 5 28.6±9.6 119.3±22.8
Chloroquine 16.1±2.6 170.1±41.3
n＝4±SD
According to the present invention, provide below and the compound of embodiment 6 and 7 data relevant and that represent with CM7/I and CM8 respectively.
Method (Trager, W. according to Trager and Jensen; Jensen, J.B.; Science 1976,193, and 673), but done some modification, keep the plasmodium falciparum substratum.With the bacterial strain W2 of the bacterial strain D10 of chloroquine sensitivity and anti-chloroquine remain on the RPMI 1640 that contains 5% hematocrit (A group positive human red blood cell) (EuroClone, Celbio) and NaHCO 3Among the 24mM, add 10% heat inactivation human plasma A group, 20mM Hepes, 2Mm glutamine.Culture remains on and contains 1%O 2, 5%CO 2, 94%N 237 ℃ of atmosphere in.Product is dissolved among water (chloroquine) or the DMSO, is diluted to substratum subsequently and obtains needed concentration (final concentration of DMSO＜1%, nontoxic) parasite.Compound is distributed on 96 orifice plates (COSTAR) of flat bottom aperture.The asynchronous distribution of culture medium that contains 1-1.5% parasitemia and 1% final concentration hematocrit is configured on the aperture, cultivates 72 hours for 37 ℃.Amending method (Makler, M. according to Makler; Hinrichs, D.; Am.J.Trop.Med.Hyg.1993,48 (2), 205; D.Monti, N.Basilico, S.Parapini, E.Pasini, P.Olliaro ﹠amp; D.Taramelli.FEBS Letters 2002,522,3), by spectrophotometry (OD 650) activity of measuring parasite serum lactic dehydrogenase (pLDH) determines parasitic growing state.The anti-malarial activity is to suppress the concentration (IC of half substratum 50) represent; Each IC 50Value all is the mean value of at least three different experiments repeating.
D10
Experiment 1 experiment 2 experiments 3 experiments 4 mean value SD
CM7/I 18.8 14.3 15.8 16.30 2.29
CM8 12.8 17.9 26.6 19.10 6.98
CQ 20.4 14.6 8.6 8.3 12.98 5.74
W2
Vari237 Vari239 Vari245 mean value SD
CM7/I 18.3 16.7 32.94 22.65 1.13
CM8 15.3 36 73.12 41.47 14.64
CQ 30 72.8 145 82.60 30.26

Claims (12)

1. with the compound shown in the following formula:
In the formula,
R is Cl, Br, trifluoromethyl;
M be 0 or part on one of them Au, Rh, Ru atom; Described part is selected from PR ' 3, wherein: when M was gold, R ' was phenyl or C2-C4 alkyl; When M is rhodium, R ’ Shi Ring octadiene; When M was ruthenium, R ' was second same quinoline acidic group; When M is gold, randomly also there is the PF that is connected with M 6 -Or NO 3 -Group; When M is rhodium or ruthenium, randomly also there is the Cl that is connected with M -
X is the group shown in the following formula,
Wherein R2 and R3 are identical or different, are H or straight or branched alkyl, are preferably (CH 2) n-CH 3, wherein n=0-10 better is 1-3; Or with-CH 3,-OCH 3,-CF 3, F, Cl, Br are single replaces or disubstituted phenyl ring;
Y is CH 2-(NH) n-(CH 2) m, n=0,1 wherein, m=0-10 is preferably 1-3;
T is the group shown in the following formula:
Figure A2006800486040002C3
Or
Figure A2006800486040003C1
Or,
Figure A2006800486040003C2
Wherein, R4 and R5 are identical or different, are H or straight or branched alkyl, are preferably (CH 2) n-CH 3, n=0-5 wherein, perhaps R4 and R5 form ring together.
2. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(four Hydrogen-pyrrolizine-7a-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine.
3. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-(2,5-dimethyl-3-{[(eight Hydrogen-quinolizine-1-ylmethyl)-amino]-methyl }-pyrroles-1-yl)-amine.
4. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-[2,5-dimethyl-3-(tetramethyleneimine-1-ylmethyl)-pyrroles-1-yl]-amine.
5. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-(3-diethylamino methyl-2,5-dimethyl-pyrroles-1-yl)-amine.
6. compound as claimed in claim 1, wherein, described compound is [3-(tertiary butyl amino-methyl)-2,5-dimethyl-pyrroles-1-yl]-(7-chloro-quinolyl-4)-amine.
7. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-(3-diethylamino methyl-2-methyl-5-phenyl-pyrroles-1-yl)-amine.
8. compound as claimed in claim 1, wherein, described compound is (7-chloro-quinolyl-4)-(3-diethylamino methyl-2-phenyl-5-methyl-pyrroles-1-yl)-amine.
9. compound as claimed in claim 1, wherein, described compound is 7-chloro-N-(2-methyl-5-phenyl-3-(tetramethyleneimine-1-ylmethyl)-1H-pyrroles-1-yl) quinoline-4-amine.
10. pharmaceutical composition, wherein said pharmaceutical composition contains just like the described compound of claim 1 to 9 as activeconstituents and pharmaceutically acceptable vehicle or carrier.
11. as the purposes of the described compound of claim 1 to 9 in the medicine of preparation treatment malaria.
12. treat because the purposes in the medicine of the malaria that the plasmodium falciparum strain of anti-chloroquine causes in preparation as the described compound of claim 1 to 9.
CNA2006800486047A 2005-10-21 2006-10-20 New anti-malaria derivatives of 4-aminoquinoline Pending CN101346381A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT002008A ITMI20052008A1 (en) 2005-10-21 2005-10-21 NEW ANTIMALARIC DERIVATIVES OF 4-AMINOCHINOLINA
ITMI2005A002008 2005-10-21

Publications (1)

Publication Number Publication Date
CN101346381A true CN101346381A (en) 2009-01-14

Family

ID=37735214

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800486047A Pending CN101346381A (en) 2005-10-21 2006-10-20 New anti-malaria derivatives of 4-aminoquinoline

Country Status (5)

Country Link
EP (1) EP1937686A1 (en)
CN (1) CN101346381A (en)
AP (1) AP2008004444A0 (en)
IT (1) ITMI20052008A1 (en)
WO (1) WO2007045987A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898369A (en) * 2012-11-05 2013-01-30 上海书亚医药科技有限公司 3-amino-7-bromoquinoline-2-ethyl formate and preparation method thereof
CN106146466A (en) * 2016-06-30 2016-11-23 珠海赛隆药业股份有限公司（长沙）医药研发中心 Vonoprazan fumarate intermediate, its preparation method and the method for preparation Vonoprazan fumarate
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2743903A1 (en) 2008-11-18 2010-05-27 The Government Of The United States Of America D.B.A.The Department Of V Eterans Affairs Compounds for treating parasitic disease
JP6026441B2 (en) 2011-03-04 2016-11-16 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Aminoquinolines as kinase inhibitors
TWI547494B (en) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 Amino quinazolines as kinase inhibitors
AR092530A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc AMINO-QUINOLINE COMPOSITE, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THIS COMPOUND FOR THE PREPARATION OF A MEDICINAL PRODUCT
TWI592417B (en) 2012-09-13 2017-07-21 葛蘭素史克智慧財產發展有限公司 Prodrugs of amino quinazoline kinase inhibitor
AR094707A1 (en) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd COMPOUND OF QUINAZOLIN-4-AMINA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE FOR THE TREATMENT OF A DISEASE MEDIATED BY THE RIP2 KINASE

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7132431B2 (en) * 2001-03-14 2006-11-07 The University Of Liverpool Anti-malarial compounds
ITMI20032044A1 (en) * 2003-10-21 2005-04-22 Univ Degli Studi Milano CHINOLIZIDINIL AND CHINOLIZIDINILALCHIL-DERIVATIVES OF 4-AMINO-CHINOLINE WITH ANTIMALARIC ACTIVITY

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102898369A (en) * 2012-11-05 2013-01-30 上海书亚医药科技有限公司 3-amino-7-bromoquinoline-2-ethyl formate and preparation method thereof
CN106146466A (en) * 2016-06-30 2016-11-23 珠海赛隆药业股份有限公司（长沙）医药研发中心 Vonoprazan fumarate intermediate, its preparation method and the method for preparation Vonoprazan fumarate
CN107915720A (en) * 2016-10-08 2018-04-17 常州市第四制药厂有限公司 The new preparation process of Wo Nuolazan
CN107915720B (en) * 2016-10-08 2020-09-11 常州市第四制药厂有限公司 Novel preparation method of Vonoprazan

Also Published As

Publication number Publication date
ITMI20052008A1 (en) 2007-04-22
EP1937686A1 (en) 2008-07-02
WO2007045987A1 (en) 2007-04-26
AP2008004444A0 (en) 2008-04-30

Similar Documents

Publication Publication Date Title
CN101346381A (en) New anti-malaria derivatives of 4-aminoquinoline
KR101549876B1 (en) Salts of the Janus kinase inhibitor (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile
CN1934113B (en) Compositions useful as inhibitors of protein kinases
CN100482664C (en) 1,5-disubstituted-3,4-dihydro-1H-pyrimido [4,5-D] pyrimidi-2-one compounds and their use in treating CSBP/P38 kinase mediated diseases
CN105601619A (en) JAK kinase modulating compounds and methods of use thereof
CN102295642A (en) 2-aryl imidazo [1,2-a] pyridine-3-acetamide derivative and preparation method as well as application thereof
JPH03504012A (en) Novel benzopyrido-piperidine, piperidylidene and piperazine compounds, compositions, methods of preparation and uses
EP2049103A2 (en) Inhibitors of undecaprenyl pyrophosphate synthase
US5240933A (en) 14-hydroxy-n-(2-methoxyethyl)-7,8-dihydromorphine and -norisomorphine, processes for the preparation thereof and the use thereof as pharmaceutical compositions
CN102295635B (en) Antitumor medicament tetralin amide compounds and pharmaceutically acceptable salts thereof as well as preparation method and application of antitumor medicament tetralin amide compounds
DE19756261A1 (en) New aryl-substituted pyridylalkane, alkene and alkyarboxylic acid amides
CN102548990A (en) Inhibitors of phosphatidylinositol 3-kinase
CN102746291B (en) 13-substituted berberine derivatives and preparation method thereof, and uses of 13-substituted berberine derivatives as anti-tuberculosis drugs
RU2268260C2 (en) Quinazoline and quinoline derivatives and medicinal agents based on thereof
CN105777633A (en) Tetrahydroisoquinoline derivative and application thereof
JP2009539854A (en) Hydrochloride of 6-methoxy-8- [4- (1- (5-fluoro) -quinolin-8-yl-piperidin-4-yl) -piperazin-1-yl] -quinoline
CN107417695A (en) Berbine derivative, its preparation method, pharmaceutical composition and anticancer usage
CN104230912B (en) Quinoline, Its Preparation Method And Use
CN101679416B (en) Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3, 4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceu
SK77096A3 (en) 6-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adreno-receptor agonists
CN102229564A (en) 4-(7-chlorine-4aminoquinoline)-5,6,7,8-tetrahydro-alpha-naphthol derivatives, preparation method and application thereof
CN102964350A (en) 7-hexahydropyrrolo[1, 2-a]pyrazinylquinolonecarboxylic acid derivative and its application in treatment of Helicobacter pylori infections
CN101974016A (en) Amide compound and preparation method and applications thereof
CN102190644B (en) Chiral 3-hydroxypyridin-4-one derivatives, synthesis and application thereof
CN102838567B (en) Benzenesulfonyl piperazine compounds or benzoyl piperazine compounds, preparation methods and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090114